R. Rao Koganty - Concepedia

Author

R. Rao Koganty

Also Known As

R Koganty, R R Koganty, R Rao Koganty, R. Koganty, R. R. KOGANTY, R. R. Koganty, R. Rao Koganty, R. Rao. Koganty, R.R. Koganty, R.Rao Koganty

Publications

2.7K

Citations

H-Index

Concepts

All Affiliations

University of Alberta Memorial Sloan Kettering Cancer Center University of Washington

About

R. Rao Koganty is an author at University of Alberta specializing in medicine, immunotherapy, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	17	1.4K
2	Biochemistry	12	14	393
3	Engineering	9	9	177
4	Natural Sciences	7	7	196
5	Allergy	1	1	207

R. Rao Koganty

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Friedhelm Helling, Shengle Zhang, A Shang, PubMed ImmunologyImmunologic MechanismImmunotherapeuticsMalignant MelanomaImmunotherapy	1995	207
Antibodies Against Mucin-Associated Sialyl-Tn Epitopes Correlate with Survival of Metastatic Adenocarcinoma Patients Undergoing Active Specific Immunotherapy with Synthetic STn Vaccine Grant D. MacLean, Mark A. Reddish, R. Rao Koganty, Journal of Immunotherapy	1996	183
Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant Grant D. MacLean, Mark Reddish, R. Rao Koganty, Cancer Immunology Immunotherapy Breast OncologyDetox AdjuvantSynthetic Sialyl-tn GlycoconjugateBreast Cancer PatientsMedicine	1993	183
Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. P Y Fung, Marian Madej, R. Rao Koganty, PubMed ImmunologySynthetic Tumor-associated GlycoconjugateImmunotherapyTumor BiologyTumor Immunology	1990	162
Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide Mark A. Reddish, Grant D. MacLean, R. Rao Koganty, International Journal of Cancer Muc1 PeptideBreast OncologyCancer ImmunosurveillanceAnti-muc1 ClassLow Dose	1998	129
Active Immunization of Human Ovarian Cancer Patients Against a Common Carcinoma (Thomsen-Friedenreich) Determinant Using a Synthetic Carbohydrate Antigen Grant D. MacLean, M. B. Bowen-Yacyshyn, John Samuel, Journal of Immunotherapy Common CarcinomaImmunologyImmunoeditingPathologyIgm Titer	1992	120
Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: Effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene Lei Ding, El–Nasir Lalani, Mark A. Reddish, Cancer Immunology Immunotherapy ImmunologyImmunoeditingHuman Muc1 GeneSynthetic PeptidesAntigen Processing	1993	114
Immune sera and monoclonal antibodies define two configurations for the sialyl Tn tumor antigen. Shengle Zhang, L A Walberg, Shunji Ogata, PubMed Immunocytochemical TechniqueImmunologyPathologyImmunotherapyTumor Biology	1995	95
Liposomal Formulations of Synthetic MUC1 Peptides: Effects of Encapsulation versus Surface Display of Peptides on Immune Responses Holly H. Guan, W Budzyński, R. Rao Koganty, Bioconjugate Chemistry	1998	95
Specificities of anti-sialyl-Tn and anti-Tn monoclonal antibodies generated using novel clustered synthetic glycopeptide epitopes Mark A. Reddish, Linda Jackson, R. Rao Koganty, Glycoconjugate Journal	1997	93

Page 1